Active — Not RecruitingNot Applicable

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

United States120 participantsStarted 2025-10-16

Plain-language summary

The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration. Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, and March 31, 2025, as part of normal patient care, will be retrospectively reviewed and analyzed.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with Crohn's Disease or Ulcerative Colitis referred to start SC vedolizumab from a VUMC IBD provider and receive at least 1 dose of subcutaneous vedolizumab * Age 18 years old or older Exclusion Criteria: * Patients prescribed SC vedolizumab from a non-VUMC provider * Patients lost to follow-up or change in provider or medication before SC formulation started

What they're measuring

Clinical Remission

Timeframe: baseline with IV dosing, and 3, 6, 9, 12 months after switching to SC

Trial details

NCT IDNCT07123350

SponsorVanderbilt University Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-31

View on ClinicalTrials.gov More Inflammatory Bowel Disease (IBD) trials